APVO — Aptevo Therapeutics Share Price
0.000.00%
Last trade - 00:00- $0.45m
- -$16.45m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.04 | ||
| Price to Tang. Book | 0.04 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -163.91% | ||
| Return on Equity | -123.53% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 4.31 | 12.29 | 3.11 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 22nd, 2016
- Public Since
- July 20th, 2016
- No. of Shareholders
- 111
- No. of Employees
- 40
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 533,464
- Address
- 2401 4th Ave Ste 1050, SEATTLE, 98121-3460
- Web
- http://aptevotherapeutics.com/
- Phone
- +1 2068380500
- Auditors
- MOSS ADAMS LLP
Upcoming Events for APVO
Aptevo Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Aptevo Therapeutics Inc Earnings Release
Similar to APVO
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Aptevo Therapeutics share price?
As of Today at 19:02 UTC, shares in Aptevo Therapeutics are trading at $0.85. This share price information is delayed by 15 minutes.
How has the Aptevo Therapeutics share price performed this year?
Shares in Aptevo Therapeutics last closed at $0.85 and the price had moved by -98.98% over the past 365 days. In terms of relative price strength the Aptevo Therapeutics share price has underperformed the S&P500 Index by -99.18% over the past year.
What are the analyst and broker recommendations for Aptevo Therapeutics?
The overall consensus recommendation for Aptevo Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Aptevo Therapeutics dividend yield?
Aptevo Therapeutics does not currently pay a dividend.
Does Aptevo Therapeutics pay a dividend?
Aptevo Therapeutics does not currently pay a dividend.
When does Aptevo Therapeutics next pay dividends?
Aptevo Therapeutics does not currently pay a dividend.
How do I buy Aptevo Therapeutics shares?
To buy shares in Aptevo Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aptevo Therapeutics?
As of the previous close price of $0.85, shares in Aptevo Therapeutics had a market capitalisation of $0.45m.
Where are Aptevo Therapeutics shares listed?
Here are the trading details for Aptevo Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: APVO
What kind of share is Aptevo Therapeutics?
Based on an overall assessment of its quality, value and momentum Aptevo Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aptevo Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Aptevo Therapeutics is $225.25. That is 26553.65% above the last closing price of $0.85.
Analysts covering Aptevo Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$31.50 for the next financial year.
What is the trend in the Aptevo Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aptevo Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -94.88%.
As of the last closing price of $0.85, shares in Aptevo Therapeutics were trading -94.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aptevo Therapeutics PE Ratio?
The Aptevo Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aptevo Therapeutics?
We do not have data on Aptevo Therapeutics' directors